Markets:

Overview

News

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

777.41 +5.30 (+0.69%)

Streaming Delayed Price Updated: 11:50 AM EDT, Aug 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

64 65 Next >

Wayfair, Qorvo, Celestica, United Parcel Service, Regeneron Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗

October 28, 2025

Via Benzinga

These S&P500 stocks that are showing activity before the opening bell on Tuesday. ↗

October 28, 2025

The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements.

Via Chartmill

Regeneron's Q3 Earnings Outperform Expectations With Dupixent Strength Balancing Eylea Weakness ↗

October 28, 2025

Regeneron posts Q3 earnings of $11.83 per share, topping estimates as Dupixent profits lift results despite weaker Eylea sales.

Via Benzinga

Earnings Scheduled For October 28, 2025 ↗

October 28, 2025

Via Benzinga

Gapping S&P500 stocks in Monday's session ↗

October 13, 2025

Via Chartmill

Why Regeneron Pharmaceuticals’ Stock Is Climbing Premarket Today ↗

October 13, 2025

Via Stocktwits

Regeneron's Earnings Took A Big Tax Hit, And Still Pounded Forecasts ↗

October 28, 2025

Regeneron stock advanced early Tuesday on better-than-expected third-quarter earnings despite a big tax hit.

Via Investor's Business Daily

Regeneron Pharmaceuticals (NASDAQ:REGN) Q3 2025 Earnings Beat Estimates ↗

October 28, 2025

Regeneron (REGN) Q3 2025 earnings beat estimates with $11.83 EPS on $3.75B revenue. Strong performance driven by Dupixent and Libtayo sales growth.

Via Chartmill

Topics Earnings

Regeneron (NASDAQ:REGN) Surprises With Strong Q3

October 28, 2025

Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q3 CY2025, but sales were flat year on year at $3.75 billion. Its non-GAAP profit of $11.83 per share was...

Via StockStory

Regeneron Reports Third Quarter 2025 Financial and Operating Results

October 28, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Market's Perilous Peak: Is the U.S. Stock Market More Overvalued Than Ever?

October 27, 2025

New York, NY – October 27, 2025 – A chorus of concern is growing louder across financial markets, with prominent voices like MarketWatch raising alarm bells over what they describe as an unprecedented...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

A Preview Of Regeneron Pharmaceuticals's Earnings ↗

October 27, 2025

Via Benzinga

Regeneron Earnings: What To Look For From REGN

October 26, 2025

Biotech company Regeneron (NASDAQ:REGN) will be announcing earnings results this Tuesday before market open. Here’s what you need to know.

Via StockStory

Topics Artificial Intelligence

Sanofi Soars as Dupixent Sales Near €5 Billion Amidst Intensifying Trump Drug Pricing Negotiations

October 24, 2025

Paris, France – October 24, 2025 – Pharmaceutical giant Sanofi (EURONEXT: SAN, NASDAQ: SNY) saw its shares climb today following the announcement of stellar third-quarter 2025 financial results,...

Via MarketMinute

Topics Government World Trade

Immuno-Oncology Stocks Q2 Recap: Benchmarking Exact Sciences (NASDAQ:EXAS)

October 21, 2025

Looking back on immuno-oncology stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Exact Sciences (NASDAQ:EXAS) and its peers.

Via StockStory

Topics Artificial Intelligence

Reflecting On Immuno-Oncology Stocks’ Q2 Earnings: Natera (NASDAQ:NTRA)

October 20, 2025

As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the immuno-oncology industry, including Natera (NASDAQ:NTRA) and its peers.

Via StockStory

Topics Artificial Intelligence

Here's How Much $1000 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today ↗

October 20, 2025

Via Benzinga

The FDA Just Granted Its Speediest Review Ever. Disc Medicine, Others Fly. ↗

October 17, 2025

The Commissioner's National Priority Review vouchers aims to speed up the review process to just one to two months.

Via Investor's Business Daily

FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times ↗

October 17, 2025

The FDA launched a new voucher program to fast-track reviews, naming nine experimental drugs for cancer, diabetes, addiction, and other conditions.

Via Benzinga

Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation

October 17, 2025

Positive opinion based on results of Phase 3 C-POST trial that show Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence...

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Revolution Medicines, Disc Medicine, Regeneron Stocks Jump After-Hours As FDA Fast-Tracks 9 Drugs Under New Review Program ↗

October 17, 2025

The FDA’s new National Priority Voucher pilot helps with faster drug reviews, cutting timelines from nearly a year to weeks.

Via Stocktwits

Regeneron Pharmaceuticals (NASDAQ:REGN) Presents a Compelling Case for Value Investors ↗

October 16, 2025

Regeneron (REGN) presents a strong value investment case with a low P/E ratio, robust financial health, high profitability, and steady growth.

Via Chartmill

EyePoint Pharmaceuticals Raises Capital As It Advances Lead Product To Pivotal Study ↗

October 15, 2025

EyePoint Pharmaceuticals outlines Phase 3 trials for Duravyu in diabetic macular edema, backed by $150 million in new funding.

Via Benzinga

Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers

October 15, 2025

New safety and pharmacokinetic data from Phase 3 C-POST trial provide insights on an every 6-week dosing regimen of adjuvant Libtayo® (cemiplimab) in high-risk cutaneous squamous cell carcinoma

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

2 Stocks Down 17% and 21% to Buy Right Now ↗

October 14, 2025

Both companies have faced recent challenges, but look likely to overcome them.

Via The Motley Fool

Topics World Trade

Why Are Regeneron And Scholar Rock Shares Falling On Monday? ↗

October 13, 2025

Regeneron and Scholar Rock’s submissions have been delayed or denied following an FDA inspection at the third-party fill-finish facility Catalent Indiana, owned by Novo Nordisk.

Via Stocktwits

Regeneron's Gene Therapy Shows Significant Gains In Genetic Hearing Loss ↗

October 13, 2025

Regeneron gene therapy for OTOF-related hearing loss shows rapid, sustained improvements, including normal hearing in some participants.

Via Benzinga

DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss

October 12, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Forecasting The Future: 9 Analyst Projections For Regeneron Pharmaceuticals ↗

October 10, 2025

Via Benzinga

Regeneron's Libtayo Gains FDA Approval To Reduce Recurrence Risk In Skin Cancer Patients ↗

October 09, 2025

FDA approves Regeneron's Libtayo for adults with high-risk cutaneous squamous cell carcinoma after surgery and radiation, based on Phase 3 trial data.

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

64 65 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.